ABSTRACT
Objective@#To observe the efficacy of the combination of chemotherapy and Ginseng Rg3 on advanced non-small cell lung cancer(NSCLC).@*Methods@#In the multi-center, large-sample, randomized, double blind trial, 414 patients with Ⅲ-Ⅳ NSCLC were enrolled.199 were in the experimental group and 215 the control group. The patients in the experimental group were treated with the standard first-line chemotherapy combined with Ginseng Rg3. The patients in the control group were treated with the same chemotherapy combined with placebo. Median overall survival (OS), Karnofsky performance scale (KPS), Traditional Chinese Medicine (TCM) symptoms score and side effects of two groups were observed as main indexes.@*Results@#The median OS were 12.03 months in the experimental group, which was significantly better than that in the control group (8.46 months, P<0.05). Hemoglobin and white blood cells were decreased after the first and second cycle of treatment in both groups. Both adverse events were significantly milder in the treatment group (P<0.05). In addition, after two courses of treatment, the KPS of patients was 78.95±9.14 in the experimental group and 76.77±9.15 in the control group, while the TCM symptoms score was 2.45±1.73 in the experimental group and 2.92±2.06 in the control group, with significant difference (P<0.05).@*Conclusions@#Combination of TCM with Western medicine such as chemotherapy could prolong the survival of patients with advanced NSCLC. The combined therapy improved patients′ symptoms and reduced chemotherapy induced myelosuppression.
ABSTRACT
Objective To observe the clinical efficacy of Zishen Pingchan Granules in treating non-motor symptoms (NMS) of Parkinson disease (PD). Methods A randomized, double-blind, placebo-controlled trial was used. 124 patients with PD were randomly divided into the treatment group (n=62) and the control group (n=62). Patients not yet taking Western medicine were suspended the application of Western medicine, receiving direct TCM treatment. Patients who had already taken Western medicine were added TCM on the basis of original medicine dosage and method. The treatment group was given Zishen Pingchan Granules, while the control group was treated with placebo granule, once a bag, twice a day. The treatment lasted for 12 weeks. The clinical efficacy was assessed by using unified PD rating scale (UPDRSⅡ–Ⅲ), the scale for outcomes in PD for autonomic symptoms (SCOPA-AUT), Parkinson disease sleep scale (PDSS) and dosage of levodopa. Results The UPDRSⅡ and UPDRS Ⅲscores of the treatment group and the control group after 4, 8, and 12 week of treatment had no difference at each time point compared with before treatment (P>0.05). There was no statistical significance in scores of UPDRSⅡ and UPDRSⅢ after treatment (P>0.05). Efficacy of SCOPA-AUT in treatment group after treatment was significantly better than the control group; There was statistical significance in constipation, salivation, nocturia and sweating in SCOPA-AUT between the two groups after treatment (P<0.05). Compared with before treatment, PDSS scores in treatment group after 8 and 12 weeks of treatment increased significantly (P<0.05). After 4, 8, and 12 weeks of treatment, PDSS scores in treatment group were much higher than control group (P<0.01). By comparing PDSS score in the two groups before and after treatment, it showed that treatment group had better efficacy in extending the time to sleep, reducing nocturia, nightmares, and hallucinations (P<0.05). After 12 weeks of treatment, dosage of levodopa in control group increased significantly, which treatment group was much lower than the control group (P<0.05). Conclusion Zishen Pingchan Granules can improve the autonomic dysfunctionin and sleep quality of PD patients, and can significantly reduce the dosage of levodopa.
ABSTRACT
Background: The vosoactive effects of proteins isolated from leech saliva and leech homogenate have been the focus of many recent studies because of its therapeutic potential. Possible nonlethal and lethal toxic effects have to be determined before any therapeutic effects could be tested. The general objective is to take the first step in drug design by performing an acute toxicity studyMethods: In this randomized, double-blind trial, Swiss mice were administered subcutaneously with varying doses of leech Hirudinaria manillensis (Lesson) homogenate and observed for possible acute toxicity. Toxidromes appearing within the two-week period after the administration of the substance were noted. Necropsy was performed on all the mice subjects. The LD(50) was computed using the log dose-response probit analysis. The doses (in g/kg body weight) were 3.54, 5.0 and 7.06Results: The LD(50) at Day 2 of Hirudinaria manillensis extract was 4.6124 g/kg body weight. The LD(50) at Day 14 was not obtained, because the test animals incurred mortalities beyond Day 2, which could be explained by a delayed toxicity of the test substance. Mice injected with 7.06 g/kg showed the most number of observable toxidromes, involving several organ systems, which generally had an early onset and persisted until the time of death of the mice. Mice treated with 3.54 g/kg showed toxidromes with early onset time, but they were not as consistent as the highest dose and the effects were generally not long-lasting. Motor activity was the most affected among the toxidromes. Gross pathologic findings revealed that the intestine, liver, heart, stomach, lungs and kidney are the commonly affected organs, which had marked changes in all dose groupsConclusions: The crude H. manillensis leech extract caused toxicity in mice, with toxidromes involving mainly the nervous system, specifically the somatosensory and neuromuscular systems. The LD(50) could not be determined in this study. However, using the data at Day 2, LD(50) was 4.6124 g/kg body weight. The LOAEL could be less than or equal to 3.54 g/kg body weight. No observable adverse effect level could not be determined. (Author)
ABSTRACT
0.05), on the 4th day 7.56?6.87 and 10.00?7.07 (P0.05). After therapy all the data of electrocardiogram, blood routine examination and blood biochemical test of the cases were without clinical significance. Conclusion:50 g/L amlexanox is effective and safe in the treatment of RAU.
ABSTRACT
OBJECTIVE:To study the effects and security of amlexanox oral coating for treatment of minor recurrent aphthous ulcer(MIAU). METHODS:A randomized double-blind experiment was carried on 42 patients with MIAU were randomly divided into experimental group(20 patients),and control group(22 patients),each group respectively administered with amlexanox coating and placebo,at the lesion site 4 times a day for 5 days.RESULTS:At 3 days,the effective rates of healing in the experimental and control group were 85.0% and 36.4%,respectively(P